SCHEMBL3590904

SCHEMBL3590904

O=C(O)CC1CCCc2ccccc21

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.52
TSHR P16473 2/20 0.51
BLM P54132 1/20 0.51
HPGD P15428 1/20 0.51
KDM4C Q9H3R0 3/20 0.50
KDM5A P29375 2/20 0.50
KDM5B Q9UGL1 2/20 0.50
HTT P42858 2/20 0.50
PPARD Q03181 1/20 0.49
ALDH1A1 P00352 2/20 0.49
TP53 P04637 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
XBP1 P17861 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30301824 1.00 FFAR1 (0.52) FFAR1TSHRBLMHPGDKDM4C
SCHEMBL3246802 0.95 FFAR1 (0.51) FFAR1TSHRBLMHPGDKDM4C
SCHEMBL7847075 0.90 FFAR1 (0.62) FFAR1PPARD
SCHEMBL7845908 0.90 FFAR1 (0.62) FFAR1PPARD
SCHEMBL1470461 0.90 FFAR1 (0.62) FFAR1PPARD
SCHEMBL2993635 0.88 KDM4C (0.49) TSHRBLMHPGDKDM4CKDM5A
SCHEMBL7038866 0.87 HAO1 (0.53) TSHRBLMKDM4CKDM5AKDM5B
SCHEMBL1568052 0.87 BLM (0.51) TSHRBLMKDM4CKDM5AKDM5B
SCHEMBL1725811 0.85 BLM (0.50) TSHRBLMKDM4CKDM5AKDM5B
SCHEMBL10584761 0.85 TSHR (0.50) TSHRBLMHPGDKDM4CKDM5A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-58029721-A None JP disclosed
JP-58015938-A None JP disclosed
JP-57209235-A None JP disclosed
US-12404265-B2 Substituted pyridine derivatives as SARM1 inhibitors NURA BIO, INC. (US) 2025-09-02 US disclosed
US-11970481-B1 Substituted pyridine derivatives as SARM1 inhibitors NURA BIO, INC. (US) 2024-04-30 US disclosed
US-20240116901-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2024-04-11 US disclosed
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2023-10-26 US disclosed
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS NURA BIO, INC. 2023-10-26 US disclosed
EP-4192828-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS Nura Bio, Inc. (US) 2023-06-14 EP disclosed
CN-115820100-A Flame-retardant coating containing polyurethane acrylate and preparation method thereof 山东奔腾漆业股份有限公司 2023-03-21 CN disclosed
US-5753662-A TREATING DOPAMINERGIC SYSTEM DISORDERS ADIR ET COMPAGNIE (FR) 1998-05-19 US disclosed
US-5684020-A ANTIPSYCHOTICS, ANTIDEPRESSANTS, TREATMENT OF DYSFUNCTION OF DOPAMINERGIC SYSTEM ADIR ET COMPAGNIE (FR) 1997-11-04 US disclosed
EP-0737189-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS PHARMACIA & UPJOHN COMPANY (US) 1996-10-16 EP disclosed
WO-1995018118-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CNS AND CARDIOVASCULAR DISORDERS THE UPJOHN COMPANY (US) 1995-07-06 WO disclosed
US-5194437-A Substituted with oxygen containing heterocycle, central nervous system disorders, neuroendocrine disorders ADIR ET COMPAGNIE (FR) 1993-03-16 US disclosed
US-4443603-A PROTEOLYTIC ENZYME INHIBITORS KOWA COMPANY LIMITED (JP) 1984-04-17 US disclosed
JP-S5829721-A TETRAHYDRONAPHTHALENE DERIVATIVE AND ITS PREPARATION SUMITOMO CHEM CO LTD 1983-02-22 JP disclosed
JP-S5815938-A OBTAINING METHOD OF OPTICALLY ACTIVE TETRAHYDRONAPHTHYLACETIC ACID DERIVATIVE SUMITOMO CHEM CO LTD 1983-01-29 JP disclosed
EP-0067561-A2 Piperazine derivatives and processes for producing them KOWA COMPANY, LTD. (JP) 1982-12-22 EP disclosed
JP-S57209235-A TETRAHYDRONAPHTHALENE DERIVATIVE AND ITS PREPARATION SUMITOMO CHEM CO LTD 1982-12-22 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12404265-B2 Substituted pyridine derivatives as SARM1 inhibitors SARM1, SARNP, ADRM1 FFAR1 4246/4885TSHR 4223/4885BLM 3424/4885
US-11970481-B1 Substituted pyridine derivatives as SARM1 inhibitors SARM1, SARNP, ADRM1 FFAR1 4246/4885TSHR 4223/4885BLM 3424/4885
US-20230339913-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS SARM1, SARNP, ADRM1 FFAR1 4246/4885TSHR 4223/4885BLM 3424/4885
US-20240116901-A1 SUBSTITUTED PYRIDINE DERIVATIVES AS SARM1 INHIBITORS SARM1, SARNP, ADRM1 FFAR1 4246/4885TSHR 4223/4885BLM 3424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.